Picture of Xbrane Biopharma AB logo

XBRANE Xbrane Biopharma AB Cashflow Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapValue Trap

Annual cashflow statement for Xbrane Biopharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
R2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSPRESSPRESS
Standards:
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-188-173-388-130-43.9
Depreciation
Non-Cash Items-6.359.27101-34.745.2
Discontinued Operations
Other Non-Cash Items
Changes in Working Capital-38.4-30.7-11930.7-252
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Other Operating Cash Flow
Cash from Operating Activities-220-194-406-134-251
Capital Expenditures-77.3-60.1-16.8-52.2-140
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items0103
Other Investing Cash Flow
Cash from Investing Activities-77.3-60.1-16.8-52.2-37.1
Financing Cash Flow Items-24.2-13.3-0.963-37.5-14.2
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities349149299244256
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash53.3-101-12958.5-38.3